Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2007

Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs.

Eswaran J, Lee WH, Debreczeni JE, Filippakopoulos P, Turnbull A, Fedorov O, Deacon SW, Peterson JR, Knapp S

Structure. 2007-2-13 . 15(2):201-13 .doi: 10.1016/j.str.2007.01.001

PMID: 17292838

2006

MAPK-specific tyrosine phosphatases: new targets for drug discovery?

Barr AJ, Knapp S

Trends Pharmacol. Sci.. 2006-8-21 . 27(10):525-30 .doi: 10.1016/j.tips.2006.08.005

PMID: 16919785

High-throughput structural characterisation of therapeutic protein targets.

Marsden BD, Sundstrom M, Knapp S

Expert Opin Drug Discov. 2006-7-1 . 1(2):123-36 .doi: 10.1517/17460441.1.2.123

PMID: 23495796

Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening.

Trosset JY, Dalvit C, Knapp S, Fasolini M, Veronesi M, Mantegani S, Gianellini LM, Catana C, Sundström M, Stouten PF, Moll JK

Proteins. 2006-7-1 . 64(1):60-7 .doi: 10.1002/prot.20955

PMID: 16568448

Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution.

Barr AJ, Debreczeni JE, Eswaran J, Knapp S

Proteins. 2006-6-1 . 63(4):1132-6 .doi: 10.1002/prot.20958

PMID: 16534812

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.

Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U

Proc. Natl. Acad. Sci. U.S.A.. 2006-5-16 . 103(20):7829-34 .doi: 10.1073/pnas.0601643103

PMID: 16684881

Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase.

Bullock AN, Debreczeni JE, Edwards AM, Sundström M, Knapp S

Proc. Natl. Acad. Sci. U.S.A.. 2006-5-16 . 103(20):7637-42 .doi: 10.1073/pnas.0601638103

PMID: 16675548

The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1.

Eswaran J, Debreczeni JE, Longman E, Barr AJ, Knapp S

Protein Sci.. 2006-5-2 . 15(6):1500-5 .doi: 10.1110/ps.062128706

PMID: 16672235

Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases.

Eswaran J, von Kries JP, Marsden B, Longman E, Debreczeni JE, Ugochukwu E, Turnbull A, Lee WH, Knapp S, Barr AJ

Biochem. J.. 2006-5-1 . 395(3):483-91 .doi: 10.1042/BJ20051931

PMID: 16441242

Ruthenium half-sandwich complexes bound to protein kinase Pim-1.

Debreczeni JE, Bullock AN, Atilla GE, Williams DS, Bregman H, Knapp S, Meggers E

Angew. Chem. Int. Ed. Engl.. 2006-2-27 . 45(10):1580-5 .doi: 10.1002/anie.200503468

PMID: 16381041